ARCH, one of life sciences’ premier investors, eyes $3B for 13th fund

ARCH Ven­ture Part­ners plans to raise $3 bil­lion for its 13th fund, per a new SEC fil­ing from this week.

The Chica­go-based ven­ture cap­i­tal firm has been one of the most high-pro­file back­ers of life sci­ences com­pa­nies for the past few decades and is be­hind many big names like Il­lu­mi­na, Al­tos Labs and Vir Biotech­nol­o­gy, among dozens of oth­ers.

The firm was the fourth most ac­tive in­vestor in pri­vate fi­nanc­ings last year, per a re­cent re­port from in­vest­ment bank William Blair, hav­ing tak­en part in 18 rounds in 2023. Or­biMed, which un­veiled $4.3 bil­lion across three new funds last fall, took first with 24 rounds. Flag­ship Pi­o­neer­ing, the in­vestor and biotech cre­ator be­hind the likes of Mod­er­na, is al­so seek­ing $3 bil­lion for its next fund, per an SEC fil­ing last No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.